As of 3:59pm ET
| +1.95 / +4.26%|
The 7 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 54.00, with a high estimate of 87.00 and a low estimate of 45.00. The median estimate represents a +13.07% increase from the last price of 47.76.
The current consensus among 8 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.